#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal squamous cell carcinoma Basal cell naevus syndrome Factor IX deficiency Congenital cystic kidney disease Conjunctivitis allergic Stargardt's disease Mastocytosis Retinopathy of prematurity Chronic kidney disease Cystic fibrosis lung Laryngeal squamous cell carcinoma Amyotrophic lateral sclerosis gene carrier Aspergillus infection Wiskott-Aldrich syndrome Chronic lymphocytic leukaemia recurrent More trials…

    Learn about Rare Diseases

    Fabry’s disease – Treatment Wiskott-Aldrich syndrome – Basic Information Cystic fibrosis lung – Trials in Disease Hereditary ataxia – Diagnostics Stevens-Johnson syndrome Thrombotic thrombocytopenic purpura – Basic Information Mantle cell lymphoma stage III – Life with Disease Alternating hemiplegia of childhood – Life with Disease Mucopolysaccharidosis I – Treatment Gaucher’s disease type III More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tilmanocept Bay 2927088 AZD4512 Calcium Folinate Pentahydrate Tetrahydrouridine Evolocumab Epinephrine Bitartrate Nitrogen Denosumab Cyclophosphamide Monohydrate Dexamfetamine Sulfate Glofitamab Isatuximab Tildrakizumab Ivabradine Epirubicin Glutenin Other Blood Products Prednisolone Sodium Phosphate Ly3473329 More therapies…

    Learn about Your Condition

    Coma Systemic lupus erythematosus Systemic sclerosis pulmonary Solitary fibrous tumour Eye disorder Post-traumatic headache Anxiety ROHHAD syndrome Andersen-Tawil syndrome Myocardial infarction Penile cancer Dystonia Acute HIV infection Combined immunodeficiency Transferrin decreased More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Bosutinib
    • Dasatinib
    Austria Bulgaria Czechia Denmark France Germany +8

  • EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pembrolizumab
    Austria Finland France Germany Italy Norway +3

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute promyelocytic leukaemia
    Investigated Drugs:
    • Arsenic Trioxide
    France Germany Italy Poland Romania Spain

  • A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    Italy Poland
Previous Page
1 … 14 15 16 17 18 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!